Navigation Links
Columbia study shows widely used artery clearing device does not help patients during heart attack

Interventional cardiologists from Columbia University Medical Center have shown that a commonly used procedure to remove fatty debris from blocked arteries during a heart attack does not improve patient outcomes.

The procedure, called distal microcirculatory protection, is commonly and successfully used during angioplasty in vein grafts and stenting in carotid arteries. The study, published in the March 2 issue of the Journal of the American Medical Association, found that the devices were successful in removing debris from the arteries in angioplasties during heart attacks, but it showed that there was no benefit to the patient.

"It's not entirely clear why the devices failed to improve patient outcomes, but it's possible that so much damage happens during a heart attack that distal protection is simply too little, too late," said Gregg W. Stone, M.D., director of research and education for the Center for Interventional Vascular Therapy at Columbia University Medical Center and New York-Presbyterian Hospital, and vice chairman of the Cardiovascular Research Foundation.

The study, which was conducted in 38 institutions in seven countries, examined 501 patients who were having heart attacks, half of whom received distal protection.

During angioplasty procedures, fatty deposits in the arteries can be dislodged and clog arteries further downstream. Distal protection devices use a specialized guidewire and catheter to collect and remove this debris.

The study evaluated the efficacy of distal protection devices using several measures, including evaluating patient ST segments ?a portion of the EKG that can indicate heart damage when it is elevated. The study showed that the percentage of patients who had normalization of the ST segment were the same, whether or not distal protection devices were used.

Within six months of the heart attack, patients had a comparable frequency of major adverse cardiac events regardless of wheth er or not they received the treatment.

The study also measured the size of the heart attacks by measuring the uptake of a tracer in the heart, and found that there was no difference for patients who received distal protection.

According to Dr. Stone, not using distal protection devices will reduce the cost of angioplasties during heart attacks, and could avoid potential complications caused by the devices.


Source:Columbia University Medical Center

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. Columbia scientists develop cancer terminator viruses
3. Contaminants linked to sturgeon decline in Columbia river
4. Columbia University licenses next-generation DNA sequencing technology
5. New bird discovered on unexplored Columbian mountain
6. Columbia scientists determine 3-dimensional structure of cells fuel gauge
7. Bioartificial kidney under study at MCG
8. W.M. Keck Foundation funds study of friendly microbes
9. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
10. Genome-wide mouse study yields link to human leukemia
11. Clam embryo study shows pollutant mixture adversely affects nerve cell development
Post Your Comments:

(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that ... and invited investors to participate via webcast. ... 1, 2015 at 11.00 a.m. Eastern Time --> ... 1, 2015 at 11.00 a.m. Eastern Time --> ... NY      Tuesday, December 1, 2015 at 11.00 ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
Breaking Biology Technology: